Literature DB >> 24246348

Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study.

Pedro W Rosário1, Wilson C Tavares1, Michelle A R Borges1, Juan Bernard N Santos1, Maria Regina Calsolari1.   

Abstract

OBJECTIVE: The objective of the present study was to validate an ultrasound (US) classification of cervical lymph nodes (LNs) in patients with papillary thyroid cancer (PTC) after thyroidectomy and radioactive iodine (131I) ablation.
METHODS: We performed a prospective study in which the patients were submitted to thyroidectomy and 131I ablation and then followed until neck US revealed LN(s) ≥5 mm. A total of 288 LNs from 112 patients with PTC were evaluated. Patient management was based on LN characteristics grouped according to the classification system studied here.
RESULTS: The presence of microcalcifications and/or cystic degeneration of cervical LNs were highly suggestive of a metastatic etiology (specificity of 99.4%). In contrast, the most sensitive finding for LNs affected by PTC was the absence of an echogenic hilum (sensitivity of 100%). In the absence of these findings (microcalcifications, cystic degeneration, echogenic hilum), a metastatic etiology was the most likely in the case of a round LN (specificity of 89%). The differentiation of a spindle-shaped LN without a visible hilum by Doppler analysis permitted us to dichotomize an initial probability of metastases of 13% in 25% (with peripheral vascularization) versus 3.3% (without peripheral vascularization).
CONCLUSIONS: Our results confirm that the classification proposed for cervical LNs in patients with PTC is valid for determining patient management following initial therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24246348     DOI: 10.4158/EP13307.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy.

Authors:  Marina S Carvalho; Pedro W Rosario; Gabriela F Mourão; Maria R Calsolari
Journal:  Endocrine       Date:  2016-11-23       Impact factor: 3.633

2.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

3.  Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.

Authors:  Pedro W Rosario; Thássio Leonardo Siman; Maria R Calsolari
Journal:  Endocrine       Date:  2014-09-11       Impact factor: 3.633

4.  Recognition of sentinel lymph nodes in patients with papillary thyroid cancer by nano-carbon and methylene blue.

Authors:  Fangzhou Liu; Yan Zhu; Yichuan Qian; Jia Zhang; Yu Zhang; Yuan Zhang
Journal:  Pak J Med Sci       Date:  2017 Nov-Dec       Impact factor: 1.088

5.  Repeat Ultrasonography in the First Years after Therapy with Radioiodine Is Not Necessary in Most Patients with Papillary Thyroid Carcinoma when Postoperative Ultrasonography Is Negative: A Reduction of Costs and False-Positives.

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Eur Thyroid J       Date:  2018-11-16

6.  Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?

Authors:  Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Int J Endocrinol       Date:  2015-08-09       Impact factor: 3.257

7.  Are Papillary Thyroid Carcinomas That Are Candidates for Active Surveillance in Fact Classical Microcarcinomas Restricted to the Gland?

Authors:  Pedro Weslley Souza Rosario; Gabriela Franco Mourão; Pedro Henrique Lopes Oliveira; Tulio Henrique Silva
Journal:  Eur Thyroid J       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.